ERBB2 and cancer: Based on the responsiveness of highly selective c-MET inhibitors to c-MET overexpressing cancer, we believe that the reduced PFS in the c-MET+ CTC high group suggests the potential effectiveness of c-MET inhibitors in treating patients with HR+/HER2− mBC.